中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (2): 180-184.doi: 10.35541/cjd.20240536

• 综述 • 上一篇    下一篇

维布妥昔单抗在治疗CD30阳性皮肤淋巴瘤中的作用及耐药机制进展

董赛1，2    姜怡1    汪旸1   

  1. 1北京大学第一医院皮肤性病科  国家皮肤与免疫疾病临床医学研究中心，北京  100034；2北京大学第二临床医学院，北京  100044
  • 收稿日期:2024-10-09 修回日期:2026-01-08 发布日期:2026-02-03
  • 通讯作者: 汪旸 E-mail:yangwang_dr@bjmu.edu.cn

Brentuximab vedotin in the treatment of CD30-positive cutaneous lymphomas: mechanisms of action and resistance

Dong Sai1,2, Jiang Yi1, Wang Yang1   

  1. 1Department of Dermatology and Venereology, Peking University First Hospital, Beijing 100034, China; 2The Second Clinical Medical College of Peking University, Beijing 100044, China
  • Received:2024-10-09 Revised:2026-01-08 Published:2026-02-03
  • Contact: Wang Yang E-mail:yangwang_dr@bjmu.edu.cn

PDF

2

摘要： 【摘要】 CD30是一种跨膜蛋白，在多种淋巴瘤的肿瘤细胞表面特异性高表达，是重要治疗靶点。抗体药物偶联物维布妥昔单抗可特异性靶向CD30后进入细胞，释放细胞毒药物诱导肿瘤细胞凋亡，并通过旁观者效应以及诱导细胞免疫原性死亡等增强抗肿瘤免疫反应。维布妥昔单抗已获批用于治疗多种CD30阳性淋巴瘤，并显示出良好的疗效和安全性。然而，部分患者出现耐药，其机制尚未完全明确。本文综述了维布妥昔单抗治疗CD30阳性皮肤淋巴瘤作用及耐药机制。

关键词: 淋巴瘤, CD30, 维布妥昔单抗, 作用机制, 肿瘤微环境, 耐药

Abstract: 【Abstract】 CD30 is a transmembrane protein highly expressed on the surface of tumor cells in many lymphomas, making it an important therapeutic target. The antibody-drug conjugate brentuximab vedotin （BV） specifically targets CD30, after which it is subsequently internalized into cells and releases its cytotoxic payload to induce tumor cell apoptosis. It also enhances antitumor immune responses through mechanisms such as the bystander effect and the induction of immunogenic cell death. BV has been approved for the treatment of various CD30-positive lymphomas, and has shown favorable efficacy and safety profiles. However, resistance to BV has emerged in some patients, and the underlying mechanisms remain unclear. This review summarizes the research progress on the mechanisms of action of and resistance to BV in the treatment of CD30-positive cutaneous lymphomas.

Key words: Lymphoma, CD30, Brentuximab vedotin, Action mechanisms, Tumor microenvironment, Drug resistance

引用本文

董赛 姜怡 汪旸. 维布妥昔单抗在治疗CD30阳性皮肤淋巴瘤中的作用及耐药机制进展[J]. 中华皮肤科杂志, 2026,59(2):180-184. doi:10.35541/cjd.20240536

Dong Sai, Jiang Yi, Wang Yang. Brentuximab vedotin in the treatment of CD30-positive cutaneous lymphomas: mechanisms of action and resistance[J]. Chinese Journal of Dermatology, 2026, 59(2): 180-184.doi:10.35541/cjd.20240536